For how we live.
In 7,530 people from two long-running cohorts, central sleep apnea with high oxygen overshoot carried elevated cardiovascular risk. The same apnea with low overshoot did not.
The ESC released updated heart failure guidance plus first-ever guidelines on cardiac rehabilitation and on cardiovascular disease with chronic kidney disease. All three sit behind a paywall.
DANISH-CRT randomised 1,000 patients to electrically targeted or conventional left ventricular lead placement. After nearly four years, death and heart failure admissions were the same.
THESUS-HF II enrolled 1,578 patients across 50 hospitals in 17 countries. Guideline drugs were prescribed at discharge in most patients, and target doses were reached in fewer than half.
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
ABYSS and SMART-DECISION together cover 6,238 stable patients. Discontinuation cleared both noninferiority margins, though the authors say the primary endpoint's composition limits what it shows.
CARDIO-TTRansform randomised 1,432 patients with transthyretin amyloid cardiomyopathy to eplontersen or placebo for 140 weeks. The confidence interval around the primary result crosses one.
A meta-analysis of 90,000 people found these diabetes-origin drugs reduced kidney disease progression by 37% and cardiovascular events by 23%, and the benefit was similar in people who did not have diabetes.
Comparing US adults vaccinated just before and just after the changeover from the live to the recombinant shingles vaccine, researchers found a 9% lower cardiovascular burden over seven years.
A first consolidated audit of PBS and PHARMAC cardiovascular listings from 2023 to 2025 finds a widening access gap between two neighbouring countries with similar disease burdens.
In 2,286 patients with sleep apnea undergoing major surgery, a measure of how deeply and how long oxygen fell — not the apnea-hypopnea index — tracked 30-day cardiovascular events and death.
PpgAge predicts chronological age from consumer wearable photoplethysmography and tracks disease. The same optical method has documented accuracy problems across skin tones.
Pooling individual data from 23,340 people in four trials, empagliflozin cut kidney failure by 34% and slowed eGFR decline by 64% — regardless of how big an initial creatinine rise was expected.
EchoNext scored 77.3% accuracy on a 150-ECG set where 13 cardiologists averaged 64.0%. Its authors released the model weights and a 100,000-ECG labelled dataset alongside the paper.